Abbott’s Ogen (estropipate)
Executive Summary
FDA approves (Nov. 10) new indication for prevention of postmenopausal osteoporosis. The estrogen replacement product has been marketed since 1977 for treatment of menopausal symptoms. Abbott filed a supplemental NDA for the new indication in 1988.